Swedbank AB Trims Stock Holdings in Danaher Corporation $DHR

Key Points

• Swedbank AB has reduced its stake in Danaher Corporation by 40%, owning approximately 1,008,338 shares worth $206.7 million after selling 673,476 shares in the first quarter.
• Point72 Asset Management L.P. significantly increased its stake in Danaher by 460.6%, acquiring 1,348,544 shares worth approximately $309.6 million.
• Danaher reported $1.80 per share earnings for the last quarter, surpassing analysts' expectations, along with a quarterly revenue of $5.94 billion.

Swedbank AB reduced its stake in Danaher Corporation (NYSE:DHR - Free Report) by 40.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,008,338 shares of the conglomerate's stock after selling 673,476 shares during the period. Swedbank AB owned approximately 0.14% of Danaher worth $206,709,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of DHR. Bank Pictet & Cie Europe AG boosted its position in shares of Danaher by 22.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock worth $44,241,000 after buying an additional 35,730 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Danaher by 7.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,534 shares of the conglomerate's stock worth $14,584,000 after purchasing an additional 4,388 shares during the period. NorthRock Partners LLC increased its stake in Danaher by 129.7% during the fourth quarter. NorthRock Partners LLC now owns 8,323 shares of the conglomerate's stock worth $1,910,000 after purchasing an additional 4,700 shares during the period. ProShare Advisors LLC increased its stake in Danaher by 12.2% during the fourth quarter. ProShare Advisors LLC now owns 98,720 shares of the conglomerate's stock worth $22,661,000 after purchasing an additional 10,770 shares during the period. Finally, Point72 Asset Management L.P. increased its stake in Danaher by 460.6% during the fourth quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock worth $309,558,000 after purchasing an additional 1,107,998 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Up 1.4%

DHR stock opened at $195.23 on Friday. The company's 50 day moving average price is $201.47 and its 200 day moving average price is $199.04. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.90. The firm has a market capitalization of $139.79 billion, a price-to-earnings ratio of 41.54, a PEG ratio of 2.69 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is 27.23%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Guggenheim reiterated a "buy" rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Wells Fargo & Company cut their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Barclays reiterated an "overweight" rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $246.35.

Insider Transactions at Danaher

In related news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.10% of the stock is owned by company insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.